KIF1A is a kinesin-family motor involved in the axonal transport of synaptic vesicle precursors (SVPs) along microtubules. In humans, more than ten point mutations in KIF1A are associated with the motor neuron disease, hereditary spastic paraplegia (SPG). However, not all of these mutations appear to inhibit the motility of the KIF1A motor, and thus, a clear molecular explanation for how KIF1A mutations lead to neuropathy is not available. In this study, we established in vitro motility assays with purified full-length human KIF1A and found that KIF1A mutations associated with the pure form of spastic paraplegia hyperactivate motility of the KIF1A motor. Introduction of the corresponding mutations into Caenorhabditis elegans KIF1A homologue unc-104 revealed abnormal accumulation of SVPs at the tips of axons and increased anterograde axonal transport of SVPs. Our data reveal that hyper-activation of kinesin motor activity, rather than its loss-of-function, is a novel cause of motor neuron disease in humans.
Introduction
Axonal transport along microtubules is fundamental for the development and maintenance of neuronal cells. Kinesin superfamily proteins (KIFs) are a large family of microtubule-dependent molecular motors, some of which are integral in driving anterograde axonal transport (1, 2) . The kinesin-3 family has been shown to transport a wide variety of cargoes (3) (4) (5) (6) . The constituents of synaptic vesicles are synthesized in the cell body and transported to synapses by vesicle carriers called synaptic vesicle precursors (SVPs) (5) . KIF1A and KIF1Bb, members of the kinesin-3 family, transport
SVPs from the cell soma to distal synapses in mammals (5, 7) . Studies in Caenorhabditis elegans (C. elegans) have revealed the basic molecular mechanism of SVP axonal transport. UNC-104, a founding member of the kinesin-3 family and a C. elegans orthologue of KIF1A and KIF1Bb, was originally discovered in C. elegans through genetic screening (8, 9) . In loss-of-function unc-104 mutants, SVPs are not properly transported to synapses, leading to abnormal accumulation of synaptic vesicles in cell bodies and dendrites (9) .
Several KIF members are known to be regulated through autoinhibitory mechanisms (10) , and the axonal transport of SVPs is known to be controlled through autoinhibition of UNC-104/KIF1A motor activity (11, 12) . Autoinhibition of KIF1A is relieved by a signaling pathway composed of BLOC-1 related complex (BORC) and a small GTPase, ARL-8 (12) (13) (14) (15) (16) . BORC acts as a guanine-nucleotide exchange factor (GEF) to facilitate the exchange of GDP for GTP in ARL-8, (15) . The GTP form of ARL-8 directly binds to and activates UNC-104 by unfolding and releasing the autoinhibition of the motor (13). The unfolded motor can then possibly dimerize (though see ( (11)) to become fully activated (17, 18) . SVPs are not properly transported to synapses in loss-of-function mutants of BORC-subunit genes and arl-8, although the phenotypes are weaker than that of the unc-104 loss-of-function mutant (14) (15) (16) .
Previously, we obtained gain-of-function unc-104 mutants through suppressor screening of arl-8 mutants (12) . These gain-of-function mutations are in the motor domain, coiled-coil 1 (CC1) domain, and coiled-coil 2 (CC2) domain (11, 18) and make UNC-104 constitutively active (12) . In mutant C. elegans that have gain-of-function unc-104 mutations, the axonal transport of SVPs is significantly increased. Thus, these mutations can suppress the reduced axonal transport observed in arl-8 and BORC-subunit mutants. These findings are consistent with previous cell biological and structural analyses of kinesin-3 family members, which show the involvement of both CC1 and CC2 in the autoinhibition (11, 18) . The mutated amino acid residues that lead to over-activation of UNC-104 are well conserved in mammalian KIF1A, and these mutations can disrupt the autoinhibition of mammalian KIF1A expressed in COS-7 cells, causing the motor to be in a constitutively active state (12) . These findings indicate that the molecular mechanisms regulating axonal transport of SVPs are very well conserved in evolution.
Hereditary spastic paraplegia (SPG) is a human motor neuron disease associated with mutations in more than 60 genes (19) . Mutations in genes encoding microtubule regulators and motor proteins, such as SPAST, KIF1A, KIF1C and KIF5A, have been identified as causes of SPG (20) (21) (22) (23) . Most KIF1A mutations associated with SPG, both autosomal dominant and recessive, are located within the conserved motor domain. In addition to SPG, de novo mutations in the motor domain of KIF1A cause mental retardation (24) . Because the motor domains of KIFs convert the energy of ATP hydrolysis into directional motility along the microtubule (25) , it is believed that disease-associated mutations in the motor domain most likely disrupt the motile mechanism of KIF1A (19, 22, 26) . Here, we show that, in contrast to this rationale, some disease-associated mutations actually lead to hyperactivation of KIF1A and thus overactive anterograde transport of axonal SVPs. Our results highlight how proper cellular control over the motile activity of microtubule-based motors is essential for neuronal homeostasis in humans.
Results

Not all disease-associated mutations in KIF1A are loss-of-function
Many disease-associated mutations have been found in the motor domain of KIF1A (24, 26, 27) . We noticed that the gain-of-function V6I mutation in unc-104, identified in our C. elegans genetic screen, is equivalent to the dominant SPG-associated mutation, V8M, in human KIF1A (12, 27) (Figs 1A and B) . Our previous data revealed that worm UNC-104(V6I) and mouse KIF1A(V8I) are constitutive active in worm neurons and COS-7 cells, respectively (12) . We thus reasoned that not all disease-associated mutations in human KIF1A result in a simple loss of motor activity. In order to explore this possibility, we first performed unc-104 complementation experiments using human KIF1A (28) . A loss-of-function allele of unc-104, unc-104(e1265), displayed strong defects in worm movement on agar plates (Fig. 1C) ; however, expression of human KIF1A rescued the unc-104(e1265) phenotype.
When human KIF1A was expressed under the unc-104 promoter, the motility in unc-104(e1265) worms was recovered to the wild-type level ( Fig. 1D and E) . Next, we expressed human KIF1A with different disease-associated mutations in unc-104(e1265) mutant worms. Expression of KIF1A(S58L), KIF1A(T99M), KIF1A(G199R), KIF1A(E253K), and KIF1A(R307Q) could not fully rescue the unc-104 mutant phenotype ( Fig. 1E ), indicating that these mutations lead to partial or full loss of KIF1A function. Consistent with our initial hypothesis that KIF1A(V8M) may be a gain-of-function mutant, expression of KIF1A(V8M) completely rescued the unc-104 mutant. Interestingly, expression of KIF1A(A255V) and KIF1A(R350G) also completely rescued the unc-104(e1265) allele (Fig. 1E ).
KIF1A mutations associated with pure SPG hyperactivate the KIF1A motor KIF1A motor activity is tightly regulated via several mechanisms, including autoinhibition and possibly by changes in the oligomeric state of the motor (11, 17, 18, 29) . Previous studies have shown that CC1 and CC2 bind to the neck coiled-coil domain and motor domain of KIF1A and inhibit its binding to microtubules (11, 12, 18) .
To test the effect of disease-associated mutations on autoinhibition, we observed the motility of KIF1A on microtubules using single molecule assays (Fig. 2) . If the autoinhibition is disrupted by disease-associated mutations, the landing rate and/or processive motility of mutant motors on microtubules should increase. Full-length human KIF1A, KIF1A(V8M), KIF1A(A255V) and KIF1A(R350G) fused to a C-terminal mScarlet-strepII tag were expressed in sf9 cells using baculovirus and purified (Figure 2A, methods) . Purified motors were diluted to 1 nM and observed by total internal reflection fluorescent (TIRF) microscopy. We observed processive movement of purified KIF1A on MTs, but the landing rate was relatively low (0.002 ± 0.004 /µm/sec at 1nM) compared to previous data obtained by the analysis of purified tail-truncated and forced-dimerized mutant of KIF1A (11, 30) (Fig. 2B and C and supplementary figure S1), consistent with the motor existing predominantly in an autoinhibited and possibly monomeric state (11, 17, 18) . Since all preparations of motors studied here were taken from the same elution fractions off of a gel filtration column, we favor the former explanation. In contrast, full-length KIF1A(V8M), KIF1A(A255V) and KIF1A(R350G) showed greatly elevated landing rates compared to the wild-type motor (Fig 2B-D) . KIF1A(V8M) had the highest landing rate (~20-fold increased compared to WT), while KIF1A(A255V) and KIF1A(R350G) were activated to a lesser extent (~10-fold compared to WT) (Fig 2D) . While the velocity of KIF1A(A255V) was comparable to wild-type KIF1A, the velocity of KIF1A(V8M) and KIF1A(R350G) was approximately 2-and 3-times faster than wild-type KIF1A, respectively (Fig. 2E) , suggesting that either these mutations relieve the autoinhibitory mechanisms to various degrees, or confer a gain of function increase in velocity. These data, together with the results from the rescue assays ( Fig. 1) , indicate that V8M, A255V and R350G are gain-of-function, rather than loss-of-function KIF1A mutations.
Establishment of an SPG model in C. elegans.
C. elegans is a good genetic model to study the molecular mechanism of axonal transport. To test the impact of disease-associated mutations on axonal transport in vivo, we established an SPG model in worms by introducing the corresponding human mutations into worm UNC-104 using genome editing. The autosomal-dominant SPG (ADSPG) mutation (V6M, corresponding to human V8M) and the autosomal-recessive SPG (ARSPG) mutation (A252V, corresponding to human A255V) were introduced into unc-104 (Fig. 3A) were co-injected as described (31) (Fig. 3B ). Sanger sequencing confirmed the successful establishment of the model strains.
Abnormal accumulation of synaptic vesicles in the distal axon in SPG model worms ALM neurons have a long axon with a single branch that extends to the nerve ring. Synapses are formed along this axon branch (Fig. 3C ). Synaptic vesicles were dispersed diffusely within the axons of wild-type worms (Fig. 3D) . In adult worms with ADSPG and ARSPG mutations, we observed an abnormal accumulation of synaptic vesicles at the tip of the main ALM axon. This phenotype was similar to that of loss-of-function dynein mutants (Fig. 3E, F ) worms were more resistant to aldicarb than the wild type (Fig 3G-I ). This result indicates that human disease-associated mutations in unc-104 cause presynaptic defects.
Human disease mutations lead to aberrant activation of synaptic vesicle precursor transport.
The small GTPase, ARL-8, is a regulator of axonal transport of SVPs (13, 14) .
In mutant worms that lack ARL-8, UNC-104 motor activity is not properly activated (12) . As a result, synaptic vesicles accumulate abnormally in the proximal asynaptic region of the DA9 axon due to reduced anterograde transport (13, 14) ( 
Increase in anterograde transport of SVPs in SPG model worms
Finally, we analyzed axonal transport of SVPs in SPG model worms by time-lapse microscopy ( Figure 5 ). Previous studies have shown that GFP::RAB-3 is a good marker to observe the axonal transport of SVPs (13, 33) . We observed the motility of vesicles carrying GFP-RAB-3 in the asynaptic region of the DA9 neuron (Fig. 4A ).
First, the velocity of the anterograde transport was faster in unc-104(ADSPG
V6M
) worms than in the wild type ( Fig. 5A, B) . However, the velocity of anterograde transport was comparable in unc-104(ARSPG
A252V
) and wild-type animals ( Fig. 5A, B ). These data are consistent with results from single molecule analysis showing that the velocity of recombinant KIF1A(V8M) is faster than that of wild-type KIF1A, while that of KIF1A(A255V) is similar to that of the wild type (Fig. 2 ).
The frequency of anterograde transport was increased in both autosomal dominant and recessive model worms ( strains (Fig 5D) . Previous studies have shown that the amount of axonal transport is determined by the dissociation rate and capture rate at vesicle pools along the axon (13).
In axonal transport, vesicles are occasionally dissociated from vesicle pools along the axon. The number of events was counted and analyzed (Fig. 5E) ; however, the dissociation rate was not significantly affected in unc-104(ADSPG
) and unc-104(ARSPG V6M ) strains. When moving vesicles reach stationary vesicle pools along the axon they are either captured, or pass through the stationary pool. We measured the probability of capture events in our data (Fig. 5F ), and found that the capture rate was decreased in both disease model strains, suggesting that axonal transport was overactive in the mutant axons. Together, these data indicate that mutant UNC-104 motor activity is upregulated, resulting in an increase in anterograde transport of SVPs in disease-model axons.
Discussion
Based on in vitro reconstitution and genetic analysis in a C. elegans model system, we suggest here that aberrant activation of KIF1A motor activity leads to human motor neuron disease. SPG is characterized by progressive spasticity in the lower limbs, and is categorized into pure and complicated forms (19) . Pure SPG affects only lower limbs, while complicated SPG causes additional neurological symptoms.
Many mutations in the motor domain of KIF1A are associated with neuronal diseases, leading to both the pure and complicated forms of SPG, as well as mental retardation (24, 26, 27) . However, it remained unknown why different mutations cause different types of diseases. Previous studies, along with the data presented here, demonstrate that KIF1A mutations that cause complicated SPG and mental retardation are loss-of-function (26, 34) (Fig. 1) . In contrast, KIF1A(V8M), KIF1A(A255V) and KIF1A(R350G) cause over-activation of KIF1A motor activity in vitro and are associated with pure SPG, suggesting that gain-of-function mutations cause the pure form of SPG. The landing rate of these mutants were much higher than wild type KIF1A, suggesting that autoinhibitory mechanism that regulate microtubule binding (11) is disrupted by these mutations. The landing rate of KIF1A(V8M) was much higher than that of KIF1A(A255V) and KIF1A(R350G) in vitro ( Fig. 2A-D were faster than wild type KIF1A (Fig 2E) . Consistent with this, the anterograde transport in unc-104(ADSPG
V6M
) worms was faster than wild type. The molecular mechanism for these velocity changes remains unclear, but the mutations could conceivably alter the motors enzymatic rate, or lead to varying degrees of release of the autoinhibition mechanisms.
Interestingly, a previous study did not detect defects in the motor activity of KIF1A(A255V) (26) . This study analyzed mutant forms of recombinant, truncated KIF1A using a multi-motor microtubule gliding assay, and found that the activity of KIF1A(A255V) is comparable to that of wild-type KIF1A. This result is reasonable because the study used a deletion mutant of KIF1A that lacked the entire tail domain, and thus any auto-regulatory elements. Moreover, in microtubule-gliding assays, motors are attached to a glass surface, which can force motors into their active conformations (35) (36) (37) . In this study, we analyzed full-length KIF1A by single-molecule motility assays in solution, which made it possible to detect defects in KIF1A autoregulation.
Similar experiments have been performed using rodent KIF1A and worm UNC-104, but these did not observe processive movement (17, 38) . Instead, artificial dimerization, artificial cargo binding, or extremely high concentrations (i.e. more than 2 µM) are required for processive movement of KIF1A and UNC-104 (17) . However, these studies used deletion mutants that largely lacked the distal C-terminal tail domain of KIF1A and UNC-104. Our results show that full-length human KIF1A is a processive motor in solution even at low nanomolar concentrations ( Fig. 2B and C) . The motor concentrations used here are comparable to in vitro studies of other dimeric motor proteins that carry out axonal transport (39, 40) . Although the distal C-terminal tail domain of KIF1A is predicted to have short coiled-coil domains that are evolutionarily conserved (5, 13), these domains were not included in previous in vitro studies (17, 38) .
We hypothesize that these domains may facilitate the dimerization of full-length KIF1A
as observed in vivo (11, 41) ; however, further studies are required to confirm this hypothesis.
Loss-of-function mutations in the dynein-dynactin complex, which drives retrograde axonal transport, also cause motor neuron diseases (19, 42, 43) . Our model worms displayed mis-accumulation of synaptic vesicle marker at the tip of axons ( Fig.   3C-F) . This phenotype is similar to loss-of-function mutants of dynein subunits ( Fig.   3C-F ). Thus, it is possible that gain-of-function mutations in KIF1A and loss-of-function mutations in dynein leads to motor neuron disease by a common mechanism. To precisely regulate KIF1A activity, a currently unknown molecular mechanism must monitor the number of synaptic vesicles and this information must feed back to the autoinhibition of the UNC-104/KIF1A motor. A CaM-dependent mechanism is a candidate for this regulation (4) . Another mechanism that may be involved is BORC-dependent regulation, which is involved in lysosomal transport and relies on KIF1Bb, another mammalian ortholog of UNC-104 (44, 45 (52, 53) . However, these studies have sometimes failed to identify the defects caused by the disease-associated mutations. It is possible that autoregulation of molecular motor activity is disrupted in these cases as well. Our results demonstrate that single molecule motility assays in solution using full-length recombinant proteins, coupled with the establishment of model worms by CRISPR/cas9, as performed in this study, is an informative and powerful way to investigate the molecular mechanism underlying neuronal diseases caused by mutations in motor protein genes. Further studies are necessary to more precisely define the full nature of KIF1A autoinhibition, and the molecular effects that the disease mutations have on this activity.
Methods
Worm genetics
C. elegans were maintained according to standard protocols (54) . 
unc-104(e1265) rescue by human KIF1A
The unc-104 promoter (Punc-104) was described previously (15) . A cDNA encoding human KIF1A was purchased from Promega Japan (Promega Japan, Tokyo, Japan 
Purification of recombinant human KIF1A
A cDNA encoding human KIF1A was amplified by PCR. A DNA fragment encoding the mScarlet::2xStrepII tag was synthesized by gBlocks (Integrated DNA Technologies, Coralville, IA, USA). These fragments were assembled in pAcebac1 (Geneva Biotech, Genève, Switzerland) by Gibson assembly (58). Full vector sequence was confirmed by Sanger sequencing. V8M, A255V and R350G mutations were introduced by PCR-based mutagenesis using KOD plus DNA polymerase as described above. A bacmid was generated by transforming DH10MultiBac (Geneva Biotech) with pAcebac1::human KIF1A::mScarlet::2xStrep tagII. sf9 cells were maintained as a shaking culture in Sf-900II serum-free medium (SFM) (Thermo Fisher Scientific) at 27°C. To prepare baculovirus, 0.9 x 10 5 sf9 cells were transferred to each well of a 6-well plate. sf9 cells were transformed with bacmid DNA by Cellfectin (Thermo Fisher Scientific). The resulting baculovirus was amplified and the P2 cell culture medium was used for protein expression.
To prepare recombinant proteins, 400 ml (2 x 10 6 cells/ml) of cells were innoculated with P2 baculovirus stocks at a dilution of X:100 and cultured for ~60
hours at 27°C. Cells were harvested by centrifugation at 3000 × g for 10 min and frozen in liquid nitrogen. Frozen cells were stored at -80°C until the purification step. 
TIRF assays
Glass chambers were prepared by acid washing as previously described (40) . 
Genome editing
Genome editing of worms was performed using the co-CRISPR method (31) . Target sequences for gRNA were 5′-TGTTCGCCCATTCAACCAA-3′ (V6M mutation) and 5′-CCGAAAGAGCCAATTCTAC-3′ (A252V mutation). Target sequences were inserted to pRB1017 (gift from Andrew Fire, Stanford University, addgene #59936).
pDD162 (a gift from Bob Goldstein, UNC Chapel Hill, addgene #47549) was used to express Cas9. pJA58 (a gift from Andrew Fire, addgene #59933) and the repair template single strand DNA (AF-ZF-827), which generates the dpy-10(cn64) mutation, were used as a co-CRISPR marker. These vectors and oligonucleotides were injected to young adult worms as described above and dpy or rol mutants were identified. Recombination was screened by PCR followed by digestion with EagI for the V6M mutation and EcoRI for the A252V mutation. For genotyping, Takara Ex Taq was used as described in the manufacturer's protocol (Takara, Tokyo, Japan). Single strand oligo DNA sequences for V6M and A252V mutations were
5′-GAATTAATTAAAACAATTTCAGATGTCATCGGTTAAAaTgGCTGTACGTGTT
CGgCCgTTCAACCAACGGGAAATCTCGAACACTTCAAAATGTGTC-3′ and
respectively.
Aldicarb resistance assay
The aldicarb resistance assay was performed as described (32) . Aldicarb was purchased from Fujifilm Wako (Tokyo, Japan). Aldicarb at 100 mM was prepared by dissolving 200 mg aldicarb in 10.5 ml 70% ethanol (Wako, Tokyo, Japan). Nematode growth medium (NGM) agar was prepared as described (54) . Before NGM agar solidification, aldicarb stock solution was added to make 1 mM NGM agar. OP50
solution was put on plates and left overnight at room temperature.
More than 50 L4 worms were picked and incubated at 20°C on normal NGM plates with OP50 feeder overnight. The next day, 20 adult worms were transferred to NGM plates with 1 mM aldicarb and OP50 feeder. Then, the number of dead worms were counted at 10 minute intervals. The results were analyzed using GraphPad PRISM 7.0c.
Analysis of synaptic vesicle localization
For steady state imaging of fluorescently tagged proteins in DA9 and ALM neurons of live C. elegans, an inverted Carl Zeiss Axio Observer Z1 microscope equipped with a 40x/1.4 objective and an LSM710 confocal scanning unit was used.
Prior to imaging, adult worms grown at 20°C were mounted onto 5% agarose pads with 1 mM levamisol in M9 buffer.
Analysis of axonal transport
Time 
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